News Nicox glaucoma drug works, but not as well as hoped Nicox has had both good and bad news from a much-anticipated phase 3 trial of its glaucoma therapy candidate NCX 470.
News Flurry of deals in biotech as M&A activity picks up After a slow couple of years, there are signs that biotech M&A activity is coming back into vogue, and a series of small transactions announced in the last few days pr
R&D Inside the new world of healthcare data These days, real-world data collection is in vogue and not hard to come by in healthcare research.
